[1] |
Hyngstrom JR, Hu CY, Xing Y, et al. Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: analysis from the National Cancer Data Base.Ann Surg Oncol, 2012, 19(9): 2814-2821.
|
[2] |
Hugen N, Verhoeven RH, Radema SA, et al. Prognosis and value of adjuvant chemotherapy in stage III mucinous colorectal carcinoma.Ann Oncol, 2013, 24(11): 2819-2824.
|
[3] |
Consorti F, Lorenzotti A, Midiri G, et al. Prognostic significance of mucinous carcinoma of colon and rectum: a prospective case-control study. J Surg Oncol, 2000, 73(2): 70-74.
|
[4] |
Hyngstrom JR, Hu CY, Xing Y, et al. Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: analysis from the National Cancer Data Base. Ann Surg Oncol, 2012, 19(9): 2814-2821.
|
[5] |
Jivapaisarnpong P, Boonthongtho K.Clinicopathological characteristics of mucinous and non-mucinous adenocarcinoma in the colonand rectum in Rajavithi Hospital, Thailand.J Med Assoc Thai, 2011, 94(Suppl 2): S41-45.
|
[6] |
Barresi V, Reggiani Bonetti L, Ieni A, et al. Prognostic significance of grading based on the counting of poorly differentiated clusters in colorectalmucinous adenocarcinoma. Hum Pathol, 2015, 46(11): 1722-1729.
|
[7] |
Zamir N, Ahmed S, Akhtar J. Mucinous adenocarcinoma of colon.APSP J Case Rep, 2010, 1(2): 20.
|
[8] |
Catalano V, Loupakis F, Graziano F, et al. Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer. Ann Oncol, 2012, 23(1): 135-141.
|
[9] |
Kim SH, Shin SJ, Lee KY, et al. Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III coloncancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study. Ann Surg Oncol, 2013, 20(11): 3407-3413.
|
[10] |
Negri FV, Wotherspoon A, Cunningham D, et al Norman AR. Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer. Ann Oncol, 2005, 16(8): 1305-1310.
|
[11] |
Javier Martinez-Useros, Maria Rodriguez-Remirez, Aurea Borrero-Palacios, et al. DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer. BMC Cancer, 2014, 14: 965.
|
[12] |
Oberholzer K, Menig M, Kreft A, et al. Rectal cancer: mucinous carcinoma on magnetic resonance imaging indicates poor response to neoadjuvant chemoradiation. Int J Radiat Oncol Biol Phys, 2012, 82(2): 842-848.
|
[13] |
Cao Y, Jin ZX, Tong XP, et al. Synergistic effects of topoisomerase Iinhibitor, SN38, on Fas-mediated apoptosis. Anticancer Res, 2010, 30(10): 3911-3917.
|
[14] |
Nöpel-Dünnebacke S, Schulmann K, Reinacher-Schick A, et al. Prognostic value of microsatellite instability and p53 expression in metastatic colorectal cancer treated with oxaliplatin and fluoropyrimidine-based chemotherapy. Z Gastroenterol, 2014, 52(12): 1394-1401.
|